OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Pagel on the Importance of Screening for Double- and Triple-Hit DLBCL

August 13th 2020

John M. Pagel, MD, PhD, discusses the importance of screening patients for double-hit and triple-hit diffuse large B-cell lymphoma.

Dr. Mesa on Developing Racially Inclusive Clinical Trials in MPNs

August 13th 2020

Ruben A. Mesa, MD, discusses the importance of developing racially inclusive clinical trials in myeloproliferative neoplasms.

Dr. Halfdanarson on Molecular Differences Between Left- Versus Right-Sided Tumors in CRC

August 12th 2020

Thorvardur (Thor) Halfdanarson, MD, discusses the molecular differences between left- versus right-sided tumors in colorectal cancer.

Dr. Hurvitz on Unmet Needs in HER2+ Breast Cancer

August 12th 2020

Sara A. Hurvitz, MD, discusses unmet needs within the field of HER2-positive breast cancer.

Dr. Shah on Updated Efficacy of JNJ-4528 in Relapsed/Refractory Myeloma

August 12th 2020

Nina Shah, MD, discusses the updated efficacy findings of JNJ-4528 from the phase 1b/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.

Dr. Shah on the Future of CAR T-Cell Therapy in Multiple Myeloma

August 12th 2020

Nina Shah, MD, discusses the future of CAR T-cell therapy in multiple myeloma.

Dr. Ghosh on the Role of MRD in CLL

August 12th 2020

Nilanjan Ghosh, MD, PhD, discusses the role of minimal residual disease in chronic lymphocytic leukemia.

Dr. Martin on the Safety Profile of Belantamab Mafodotin in R/R Multiple Myeloma

August 12th 2020

Thomas G. Martin, MD, discusses the safety profile of belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.

Dr. Mascarenhas Discusses Ongoing Clinical Trials in Myelofibrosis

August 12th 2020

John O. Mascarenhas, MD, discusses ongoing clinical trials in myelofibrosis.

Dr. Nowakowski on Potential Clinical Implications of the ENGINE Study in DLBCL

August 12th 2020

Grzegorz S. Nowakowski, MD, discusses the potential clinical implications of the ongoing, randomized phase 3 ENGINE study in patients with high-risk Denovo Genomic Marker 1–positive diffuse large B-cell lymphoma.

Dr. Woyach on the Role of Chemoimmunotherapy in CLL

August 11th 2020

Jennifer Woyach, MD, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia.

Dr. Burris on Treatment Considerations in TNBC

August 11th 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses treatment considerations in triple-negative breast cancer.

Dr. Monk on Emerging Therapies in Cervical Cancer

August 11th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses emerging therapies in cervical cancer.

Dr. Khong on the Potential Benefit of IO/Endocrine Therapy in ER+ Breast Cancer

August 11th 2020

Hung Khong, MD, discusses the potential benefit of combining immunotherapy with endocrine therapy in estrogen receptor–positive, HER2-negative breast cancer.

Dr. O'Donnell Discusses Ongoing Research Efforts in Multiple Myeloma

August 11th 2020

Betsy O'Donnell, MD, discusses ongoing research efforts in multiple myeloma.

Dr. Tykodi on the KEYNOTE-427 Trial With Pembrolizumab in RCC

August 11th 2020

Scott S. Tykodi, MD, PhD, provides background to the phase 2 KEYNOTE-427 trial with pembrolizumab in renal cell carcinoma.

Dr. Abraham on Key Considerations in the Management of TGCT

August 11th 2020

John A. Abraham, MD, FACS, discusses key considerations regarding the management of tenosynovial giant cell tumor.

Dr. Mehta on the Evolution of Treatment in Gastric and GEJ Cancers

August 11th 2020

Rutika J. Mehta, MD, MPH, discusses how treatment has evolved in recent years for gastric and gastroesophageal junction cancers.

Dr. Jacobson on the Interim Analysis of the MZL Cohort in the ZUMA-5 Trial

August 11th 2020

Caron Jacobson, MD, discusses the interim analysis results of the marginal zone lymphoma cohort in the phase 2 ZUMA-5 study with axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Davids on Remaining Questions With Umbralisib/Ibrutinib in CLL and MCL

August 10th 2020

Matthew S. Davids, MD, MMSc, discusses remaining questions with umbralisib plus ibrutinib in chronic lymphocytic leukemia and mantle cell lymphoma.